WHO Sounds Warning Over Acute Lack of Weight-Loss Medications
Less than 10% of people that would benefit from weight-loss injections like Wegovy have access to them, states the World Health Organization as it releases its first recommendations on the drugs.
Considering over a billion people worldwide currently obese, it is calling for broader and more equitable availability to GLP-1 medication.
Based on forecasts, more than two billion could be obese by 2030 without intervention.
"The latest guidelines acknowledges that obesity is a long-term condition that can be addressed with holistic and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key hurdles to universal availability to the jabs that can assist patients in reducing substantial body mass, explains the body.
GLP-1 Therapy Scarcity
Even under the current most favorable case, the supply of such drugs could only cover around 100 million people – less than 10% of eligible patients, per the health organization.
The guideline calls on governments and firms to widen access, through strategies like licensing agreements.
Exclusive production rights on the active ingredient – the main ingredient of a leading brand – is due to expire in several countries in 2026.
The Way Weight-Loss Jabs Work
GLP-1 drugs replicate a biological compound to slow digestion, curb appetite and boost the sense of being full so individuals reduce food intake.
Individuals usually begin shedding pounds within a few weeks of starting on the regular doses.
Evidence suggests patients may regain a significant portion after a year of halting the treatment, because their typical appetite come back.
Being carrying excess weight raises your likelihood for developing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight affects people in countries worldwide and was responsible for millions of deaths worldwide in 2024, per the WHO.
